Univar Solutions

Company snapshot

Univar Solutions Inc. (formerly [Royal Vopak](en.wikipedia.org/wiki/Vopak)) is a global chemical and ingredients distributor and provider of value-added services. Founded in 1924 as Van Waters & Rogers, it was acquired in August 2023 by funds controlled by [Apollo Global Management](en.wikipedia.org/wiki/Apollo_Global_Mana). The transaction also included [Abu Dhabi Investment Authority](en.wikiped

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Univar Solutions. Not investment advice.

• What is Univar Solutions?

  Univar Solutions is a pharma organization headquartered in EU. Primary therapeutic focus areas include Wilson’s Disease. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO source

• Is Univar Solutions publicly traded?

  Univar Solutions appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Univar Solutions develop or market?

  We link 3 drug profile(s) where Univar Solutions is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/univar-solutions-bv#company-drugs.

• What are the latest developments for Univar Solutions?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Univar Solutions focus on?

  Univar Solutions focuses on Wilson’s Disease based on our analysis of their pipeline programs and drug development activities.